Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 53 entries
View as:

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT06015282 Org: User:
Start: 11/03/23 End: 01/30/25 Due: 01/30/26

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Phase: N/A Priority: Normal
NCT ID: NCT03314662 Org: User:
Start: 10/17/17 End: 05/17/18 Due: 05/17/19

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

Phase: N/A Priority: Normal
NCT ID: NCT00479648 Org: User:
Start: 05/31/07 End: 08/31/07 Due: 08/31/08

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Phase: N/A Priority: Normal
NCT ID: NCT00958243 Org: User:
Start: 08/31/09 End: 04/30/10 Due: 04/30/11

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Phase: N/A Priority: Normal
NCT ID: NCT00812019 Org: User:
Start: 11/30/08 End: 11/30/10 Due: 11/30/11

Flucelvax (TIVc or QIVc) Pregnancy Registry

Phase: N/A Priority: Normal
NCT ID: NCT03438487 Org: User:
Start: 09/01/17 End: 12/31/20 Due: 12/31/21

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT00735475 Org: User:
Start: 10/31/08 End: 06/30/09 Due: 06/30/10

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Phase: N/A Priority: Normal
NCT ID: NCT02126761 Org: User:
Start: 06/30/14 End: 11/30/15 Due: 11/30/16

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Phase: N/A Priority: Normal
NCT ID: NCT05875961 Org: User:
Start: 06/15/23 End: 11/15/24 Due: 11/15/25

Efficacy Study With QIVc in Pediatric Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03932682 Org: User:
Start: 05/13/19 End: 02/13/24 Due: 02/13/25

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Phase: N/A Priority: Normal
NCT ID: NCT02914275 Org: User:
Start: 09/27/16 End: 08/11/17 Due: 08/11/18

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT05044195 Org: User:
Start: 09/30/21 End: 09/09/22 Due: 09/09/23

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

Phase: N/A Priority: Normal
NCT ID: NCT00958126 Org: User:
Start: 08/31/09 End: 04/30/10 Due: 04/30/11

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

Phase: N/A Priority: Normal
NCT ID: NCT00700193 Org: User:
Start: 03/31/05 End: - Due: -

Study of a Pandemic Influenza Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT00136331 Org: User:
Start: 10/31/05 End: 11/30/06 Due: 11/30/07

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT02107807 Org: User:
Start: 04/30/14 End: 05/31/15 Due: 05/31/16

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00888381 Org: User:
Start: 05/31/09 End: 05/31/09 Due: 05/31/10

A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01857297 Org: User:
Start: 05/31/13 End: 06/30/13 Due: 06/30/14

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT06087640 Org: User:
Start: 10/23/23 End: 12/31/26 Due: 12/31/27

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT02545543 Org: User:
Start: 09/30/15 End: 06/30/16 Due: 06/30/17

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Phase: N/A Priority: Normal
NCT ID: NCT05874713 Org: User:
Start: 06/07/23 End: 09/25/24 Due: 09/25/25

A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01591837 Org: User:
Start: 05/31/12 End: 06/30/12 Due: 06/30/13

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Phase: N/A Priority: Normal
NCT ID: NCT02212106 Org: User:
Start: 09/30/14 End: 12/31/14 Due: 12/31/15

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT04669691 Org: User:
Start: 12/19/20 End: 04/15/22 Due: 04/15/23

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05

Phase: N/A Priority: Normal
NCT ID: NCT02255409 Org: User:
Start: 10/31/14 End: 01/31/16 Due: 01/31/17